TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
Identifieur interne : 001008 ( Ncbi/Merge ); précédent : 001007; suivant : 001009TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
Auteurs : Bantari Wk Wardhani [Indonésie] ; Meidi Utami Puteri [Japon] ; Yukihide Watanabe [Japon] ; Melva Louisa [Indonésie] ; Rianto Setiabudy [Indonésie] ; Mitsuyasu Kato [Japon]Source :
- Journal of Experimental Pharmacology [ 1179-1454 ] ; 2020.
Abstract
Triple-negative breast cancer (TNBC) is a refractory type of breast cancer with poor prognosis and limited choice for treatment. Previous studies had shown that TNBC has high expressions of transmembrane prostate androgen-induced protein (TMEPAI). TMEPAI was known to be induced by TGF-β/Smad signaling and have tumorigenic functions that converting TGF-β from tumor suppressor to tumor promoter and inducing epithelial–mesenchymal transition (EMT). Therefore, we aimed to define the role of TMEPAI in triple-negative breast cancer cells treatment using several anti-cancers in the presence of TGF-β.
TMEPAI-knock out (KO) was carried out in a triple-negative breast cancer cell, BT549. TMEPAI editing was developed using the CRISPR-Cas9 system using two combinations of sgRNA to remove exon 4 of the TMEPAI gene entirely. Genotyping and proteomic analysis were performed to check the establishment of the TMEPAI-KO cells. Wild type (WT) and KO cells were used to determine inhibitory concentration 50% (IC50) of several anti-cancers: doxorubicin, cisplatin, paclitaxel, and bicalutamide in the presence of TGF-β treatment.
KO cells were successfully established by completely removing the TMEPAI gene, which was proven in genomic and proteomic analysis. Further, in TMEPAI-KO cells, we found a significant reduction of IC50 for doxorubicin and paclitaxel, and minimal effects were seen for cisplatin and bicalutamide. Our findings suggest that TGF-β-induced TMEPAI attenuates the response of TNBC to doxorubicin and paclitaxel, but not to cisplatin and bicalutamide.
TGF-β induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide. Further study is needed to confirm our findings in other growth factor-induced cells, as well as in in vivo model.
Url:
DOI: 10.2147/JEP.S235233
PubMed: 32158279
PubMed Central: 6986256
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000674
- to stream Pmc, to step Curation: 000674
- to stream Pmc, to step Checkpoint: 000035
Links to Exploration step
PMC:6986256Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</title>
<author><name sortKey="Wardhani, Bantari Wk" sort="Wardhani, Bantari Wk" uniqKey="Wardhani B" first="Bantari Wk" last="Wardhani">Bantari Wk Wardhani</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</nlm:aff>
<country xml:lang="fr">Indonésie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Puteri, Meidi Utami" sort="Puteri, Meidi Utami" uniqKey="Puteri M" first="Meidi Utami" last="Puteri">Meidi Utami Puteri</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Watanabe, Yukihide" sort="Watanabe, Yukihide" uniqKey="Watanabe Y" first="Yukihide" last="Watanabe">Yukihide Watanabe</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Louisa, Melva" sort="Louisa, Melva" uniqKey="Louisa M" first="Melva" last="Louisa">Melva Louisa</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</nlm:aff>
<country xml:lang="fr">Indonésie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Setiabudy, Rianto" sort="Setiabudy, Rianto" uniqKey="Setiabudy R" first="Rianto" last="Setiabudy">Rianto Setiabudy</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</nlm:aff>
<country xml:lang="fr">Indonésie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kato, Mitsuyasu" sort="Kato, Mitsuyasu" uniqKey="Kato M" first="Mitsuyasu" last="Kato">Mitsuyasu Kato</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">32158279</idno>
<idno type="pmc">6986256</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986256</idno>
<idno type="RBID">PMC:6986256</idno>
<idno type="doi">10.2147/JEP.S235233</idno>
<date when="2020">2020</date>
<idno type="wicri:Area/Pmc/Corpus">000674</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000674</idno>
<idno type="wicri:Area/Pmc/Curation">000674</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000674</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000035</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000035</idno>
<idno type="wicri:Area/Ncbi/Merge">001008</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</title>
<author><name sortKey="Wardhani, Bantari Wk" sort="Wardhani, Bantari Wk" uniqKey="Wardhani B" first="Bantari Wk" last="Wardhani">Bantari Wk Wardhani</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</nlm:aff>
<country xml:lang="fr">Indonésie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Puteri, Meidi Utami" sort="Puteri, Meidi Utami" uniqKey="Puteri M" first="Meidi Utami" last="Puteri">Meidi Utami Puteri</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Watanabe, Yukihide" sort="Watanabe, Yukihide" uniqKey="Watanabe Y" first="Yukihide" last="Watanabe">Yukihide Watanabe</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Louisa, Melva" sort="Louisa, Melva" uniqKey="Louisa M" first="Melva" last="Louisa">Melva Louisa</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</nlm:aff>
<country xml:lang="fr">Indonésie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Setiabudy, Rianto" sort="Setiabudy, Rianto" uniqKey="Setiabudy R" first="Rianto" last="Setiabudy">Rianto Setiabudy</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</nlm:aff>
<country xml:lang="fr">Indonésie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kato, Mitsuyasu" sort="Kato, Mitsuyasu" uniqKey="Kato M" first="Mitsuyasu" last="Kato">Mitsuyasu Kato</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</nlm:aff>
<country xml:lang="fr">Japon</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Experimental Pharmacology</title>
<idno type="eISSN">1179-1454</idno>
<imprint><date when="2020">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S2001"><title>Purpose</title>
<p>Triple-negative breast cancer (TNBC) is a refractory type of breast cancer with poor prognosis and limited choice for treatment. Previous studies had shown that TNBC has high expressions of transmembrane prostate androgen-induced protein (TMEPAI). TMEPAI was known to be induced by TGF-β/Smad signaling and have tumorigenic functions that converting TGF-β from tumor suppressor to tumor promoter and inducing epithelial–mesenchymal transition (EMT). Therefore, we aimed to define the role of TMEPAI in triple-negative breast cancer cells treatment using several anti-cancers in the presence of TGF-β.</p>
</sec>
<sec id="S2002"><title>Methods</title>
<p>TMEPAI-knock out (KO) was carried out in a triple-negative breast cancer cell, BT549. TMEPAI editing was developed using the CRISPR-Cas9 system using two combinations of sgRNA to remove exon 4 of the TMEPAI gene entirely. Genotyping and proteomic analysis were performed to check the establishment of the TMEPAI-KO cells. Wild type (WT) and KO cells were used to determine inhibitory concentration 50% (IC<sub>50</sub>
) of several anti-cancers: doxorubicin, cisplatin, paclitaxel, and bicalutamide in the presence of TGF-β treatment.</p>
</sec>
<sec id="S2003"><title>Results</title>
<p>KO cells were successfully established by completely removing the TMEPAI gene, which was proven in genomic and proteomic analysis. Further, in TMEPAI-KO cells, we found a significant reduction of IC<sub>50</sub>
for doxorubicin and paclitaxel, and minimal effects were seen for cisplatin and bicalutamide. Our findings suggest that TGF-β-induced TMEPAI attenuates the response of TNBC to doxorubicin and paclitaxel, but not to cisplatin and bicalutamide.</p>
</sec>
<sec id="S2004"><title>Conclusion</title>
<p>TGF-β induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide. Further study is needed to confirm our findings in other growth factor-induced cells, as well as in in vivo model.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">J Exp Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">JEP</journal-id>
<journal-id journal-id-type="pmc">jexpharm</journal-id>
<journal-title-group><journal-title>Journal of Experimental Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1179-1454</issn>
<publisher><publisher-name>Dove</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">32158279</article-id>
<article-id pub-id-type="pmc">6986256</article-id>
<article-id pub-id-type="publisher-id">235233</article-id>
<article-id pub-id-type="doi">10.2147/JEP.S235233</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group><article-title>TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel</article-title>
<alt-title alt-title-type="running-authors">Wardhani et al</alt-title>
<alt-title alt-title-type="running-title">Wardhani et al</alt-title>
</title-group>
<contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7376-6187</contrib-id>
<name><surname>Wardhani</surname>
<given-names>Bantari WK</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1550-8627</contrib-id>
<name><surname>Puteri</surname>
<given-names>Meidi Utami</given-names>
</name>
<xref ref-type="aff" rid="AFF0002">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Watanabe</surname>
<given-names>Yukihide</given-names>
</name>
<xref ref-type="aff" rid="AFF0002">2</xref>
</contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9451-0380</contrib-id>
<name><surname>Louisa</surname>
<given-names>Melva</given-names>
</name>
<xref ref-type="corresp" rid="AN0001"></xref>
<xref ref-type="aff" rid="AFF0003">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Setiabudy</surname>
<given-names>Rianto</given-names>
</name>
<xref ref-type="aff" rid="AFF0003">3</xref>
</contrib>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9905-2473</contrib-id>
<name><surname>Kato</surname>
<given-names>Mitsuyasu</given-names>
</name>
<xref ref-type="aff" rid="AFF0002">2</xref>
</contrib>
<aff id="AFF0001"><label>1</label>
<institution>Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</aff>
<aff id="AFF0002"><label>2</label>
<institution>Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences and Faculty of Medicine, University of Tsukuba</institution>
,<addr-line>Tsukuba</addr-line>
,<country>Japan</country>
</aff>
<aff id="AFF0003"><label>3</label>
<institution>Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia</institution>
,<addr-line>Jakarta</addr-line>
,<country>Indonesia</country>
</aff>
</contrib-group>
<author-notes><corresp id="AN0001">Correspondence: Melva Louisa <institution>Department of Pharmacology and Therapeutics, Faculty of Medicine Universitas Indonesia</institution>
, <addr-line>Jl Salemba Raya No. 6, Jakarta Pusat</addr-line>
, <addr-line>Jakarta</addr-line>
<addr-line>10430</addr-line>
, <country>Indonesia</country>
<phone>Tel +62 21 31930481</phone>
Email melva.louisa@gmail.com</corresp>
</author-notes>
<pub-date pub-type="epub"><day>23</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection"><year>2020</year>
</pub-date>
<volume>12</volume>
<fpage>17</fpage>
<lpage>26</lpage>
<history><date date-type="received"><day>18</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted"><day>07</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions><copyright-statement>© 2020 Wardhani et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Wardhani et al.</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>
). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>
).</license-p>
</license>
</permissions>
<abstract><sec id="S2001"><title>Purpose</title>
<p>Triple-negative breast cancer (TNBC) is a refractory type of breast cancer with poor prognosis and limited choice for treatment. Previous studies had shown that TNBC has high expressions of transmembrane prostate androgen-induced protein (TMEPAI). TMEPAI was known to be induced by TGF-β/Smad signaling and have tumorigenic functions that converting TGF-β from tumor suppressor to tumor promoter and inducing epithelial–mesenchymal transition (EMT). Therefore, we aimed to define the role of TMEPAI in triple-negative breast cancer cells treatment using several anti-cancers in the presence of TGF-β.</p>
</sec>
<sec id="S2002"><title>Methods</title>
<p>TMEPAI-knock out (KO) was carried out in a triple-negative breast cancer cell, BT549. TMEPAI editing was developed using the CRISPR-Cas9 system using two combinations of sgRNA to remove exon 4 of the TMEPAI gene entirely. Genotyping and proteomic analysis were performed to check the establishment of the TMEPAI-KO cells. Wild type (WT) and KO cells were used to determine inhibitory concentration 50% (IC<sub>50</sub>
) of several anti-cancers: doxorubicin, cisplatin, paclitaxel, and bicalutamide in the presence of TGF-β treatment.</p>
</sec>
<sec id="S2003"><title>Results</title>
<p>KO cells were successfully established by completely removing the TMEPAI gene, which was proven in genomic and proteomic analysis. Further, in TMEPAI-KO cells, we found a significant reduction of IC<sub>50</sub>
for doxorubicin and paclitaxel, and minimal effects were seen for cisplatin and bicalutamide. Our findings suggest that TGF-β-induced TMEPAI attenuates the response of TNBC to doxorubicin and paclitaxel, but not to cisplatin and bicalutamide.</p>
</sec>
<sec id="S2004"><title>Conclusion</title>
<p>TGF-β induced TMEPAI contributes to the reduced response of TNBC treatment to doxorubicin and paclitaxel, but minimal on cisplatin and bicalutamide. Further study is needed to confirm our findings in other growth factor-induced cells, as well as in in vivo model.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author"><title>Keywords</title>
<kwd>TMEPAI</kwd>
<kwd>TGF-β</kwd>
<kwd>doxorubicin</kwd>
<kwd>paclitaxel</kwd>
</kwd-group>
<counts><fig-count count="4"></fig-count>
<table-count count="1"></table-count>
<ref-count count="52"></ref-count>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
</pmc>
<affiliations><list><country><li>Indonésie</li>
<li>Japon</li>
</country>
</list>
<tree><country name="Indonésie"><noRegion><name sortKey="Wardhani, Bantari Wk" sort="Wardhani, Bantari Wk" uniqKey="Wardhani B" first="Bantari Wk" last="Wardhani">Bantari Wk Wardhani</name>
</noRegion>
<name sortKey="Louisa, Melva" sort="Louisa, Melva" uniqKey="Louisa M" first="Melva" last="Louisa">Melva Louisa</name>
<name sortKey="Setiabudy, Rianto" sort="Setiabudy, Rianto" uniqKey="Setiabudy R" first="Rianto" last="Setiabudy">Rianto Setiabudy</name>
</country>
<country name="Japon"><noRegion><name sortKey="Puteri, Meidi Utami" sort="Puteri, Meidi Utami" uniqKey="Puteri M" first="Meidi Utami" last="Puteri">Meidi Utami Puteri</name>
</noRegion>
<name sortKey="Kato, Mitsuyasu" sort="Kato, Mitsuyasu" uniqKey="Kato M" first="Mitsuyasu" last="Kato">Mitsuyasu Kato</name>
<name sortKey="Watanabe, Yukihide" sort="Watanabe, Yukihide" uniqKey="Watanabe Y" first="Yukihide" last="Watanabe">Yukihide Watanabe</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001008 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001008 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Ncbi |étape= Merge |type= RBID |clé= PMC:6986256 |texte= TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:32158279" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |